{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:02:00Z","timestamp":1758844920501,"version":"3.44.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":3658,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1111\/j.1523-1755.2005.09927.x","type":"journal-article","created":{"date-parts":[[2005,11,15]],"date-time":"2005-11-15T14:45:27Z","timestamp":1132065927000},"page":"S152-S156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S99","title":["Clinical benefits of slowing the progression of renal failure"],"prefix":"10.1016","volume":"68","author":[{"given":"Francesco","family":"Locatelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Del Vecchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Pozzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0010","first-page":"69","article-title":"The Medicare experience with end-stage renal disease: Trends in incidence, prevalence, and survival","volume":"5","author":"Eggers","year":"1984","journal-title":"Health Care Fin Rev"},{"year":"2004","series-title":"USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States","author":"United STATES RENAL DATA SYSTEM","key":"10.1111\/j.1523-1755.2005.09927.x_bb0015"},{"issue":"Suppl 3","key":"10.1111\/j.1523-1755.2005.09927.x_bb0020","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal disease","volume":"32","author":"Foley","year":"1998","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 74","key":"10.1111\/j.1523-1755.2005.09927.x_bb0025","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1046\/j.1523-1755.2000.07416.x","article-title":"Patient selection affects end-stage renal disease outcome comparisons","volume":"57","author":"Locatelli","year":"2000","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0030","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinte.164.6.659","article-title":"Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization","volume":"164","author":"Keith","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0035","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/0140-6736(91)92977-A","article-title":"Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group","volume":"337","author":"Locatelli","year":"1991","journal-title":"Lancet"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0040","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood pressure control on the progression of renal disease","volume":"330","author":"Klahr","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0045","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/ndt\/14.6.1360","article-title":"How long can dialysis be postponed by low protein diet and ACE inhibitors?","volume":"14","author":"Locatelli","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0050","doi-asserted-by":"crossref","first-page":"342","DOI":"10.7326\/0003-4819-142-5-200503010-00009","article-title":"The effect of a lower target blood pressure on the progression of kidney disease: Long-term follow-up of the modification of diet in renal disease study","volume":"142","author":"Sarnak","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0055","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0060","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0065","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0070","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","author":"The GISEN GROUP (GRUPPO ITALIANO DI STUDI EPIDEMIOLOGICI IN NEFROLOGIA)","year":"1997","journal-title":"Lancet"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0075","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0080","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0085","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Reno-protective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0090","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(05)71082-5","article-title":"REIN-2 Study Group: Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): Multicentre, randomised controlled trial","volume":"365","author":"Ruggenenti","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0095","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","article-title":"Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial","volume":"361","author":"Nakao","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0100","first-page":"119A","volume":"15","author":"Owda","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0105","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1093\/ndt\/12.9.1908","article-title":"Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency","volume":"12","author":"Samuelsson","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0110","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1523-1755.2000.00165.x","article-title":"Plasma lipids and risk of developing renal dysfunction: The atherosclerosis risk in communities study","volume":"58","author":"Muntner","year":"2000","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0115","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.yexmp.2003.08.002","article-title":"Fluvastatin prevents nephropathy likely through suppression of connective tissue growth factor-mediated extracellular matrix accumulation","volume":"76","author":"Song","year":"2004","journal-title":"Exp Mol Pathol"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0120","doi-asserted-by":"crossref","first-page":"F46","DOI":"10.1152\/ajprenal.00428.2002","article-title":"Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy","volume":"286","author":"Li","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0125","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1046\/j.1523-1755.2001.00487.x","article-title":"Effect of lipid reduction on the progression of renal disease: A meta-analysis","volume":"59","author":"Fried","year":"2001","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0130","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1053\/ajkd.2003.50140","article-title":"A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease","volume":"41","author":"Bianchi","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial","volume":"360","author":"Heart PROTECTION STUDY COLLABORATIVE GROUP","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0140","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.CIR.0000143892.84582.60","article-title":"Effect of pravastatin on cardiovascular events in people with chronic kidney disease","volume":"110","author":"Tonelli","year":"2004","journal-title":"Circulation"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0145","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/archinte.162.12.1401","article-title":"Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988\u20131994)","volume":"162","author":"Astor","year":"2002","journal-title":"Arch Int Med"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0150","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0272-6386(00)70334-9","article-title":"Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure","volume":"35","author":"Hayashi","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0155","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"New Engl J Med"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0160","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/ndt\/18.2.353","article-title":"A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients","volume":"18","author":"Furuland","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0165","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/01.ASN.0000102471.89084.8B","article-title":"Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): Results of a randomized clinical trial","volume":"15","author":"Roger","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0170","first-page":"1029","article-title":"Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure","volume":"19","author":"Locatelli","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0175","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000190270","article-title":"Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients","volume":"77","author":"Kuriyama","year":"1997","journal-title":"Nephron"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0180","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/ndt\/16.2.307","article-title":"Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients","volume":"16","author":"Jungers","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0185","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1523-1755.2004.00797.x","article-title":"Treating anemia early in renal failure patients slows the decline of renal function: A randomised controlled trial","volume":"66","author":"Gouva","year":"2004","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0190","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium \u00d7 phosphate product with mortality risk in chronic hemodialysis patients: A national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0195","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0200","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ndt\/9.8.1097","article-title":"Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus","volume":"9","author":"Biesenbach","year":"1994","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0205","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0272-6386(00)70017-5","article-title":"Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension","volume":"35","author":"Regalado","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1523-1755.2005.09927.x_bb0210","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1053\/ajkd.2001.28619","article-title":"An economic evaluation of early versus late referral of patients with progressive renal insufficiency","volume":"38","author":"Mclaughlin","year":"2001","journal-title":"Am J Kidney Dis"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815512969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815512969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:48:11Z","timestamp":1758761291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815512969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":41,"alternative-id":["S0085253815512969"],"URL":"https:\/\/doi.org\/10.1111\/j.1523-1755.2005.09927.x","relation":{},"ISSN":["0085-2538"],"issn-type":[{"type":"print","value":"0085-2538"}],"subject":[],"published":{"date-parts":[[2005,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical benefits of slowing the progression of renal failure","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1523-1755.2005.09927.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}